Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03410654 · ClinicalTrials.gov registry record · Early Phase 1
Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 28
- Enrollment target
NCT03410654: Completed Early Phase 1 study, sponsored by Yale University.
NCT03410654 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 28 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03410654, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if cognitive function improves in patients converted from tacrolimus immediate release (TAC IR) to Envarsus XR® (tacrolimus extended release) using an objective measure of cognition.
Primary Outcome
cognitive assessment at baseline using MoCA test 7.1
Interventions
- DRUG Tacrolimus, Extended Release, (Envarsus Xr)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-10-24 |
| Est. Completion | 2024-07-01 |
| Phase | Early Phase 1 |
What the finished NCT03410654 record still lists
NCT03410654 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 1 intervention - of which Tacrolimus, Extended Release, (Envarsus Xr) is the first listed.
NCT03410654 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03410654 about?
NCT03410654 is a clinical study titled "Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.". The purpose of this study is to determine if cognitive function improves in patients converted from tacrolimus immediate release (TAC IR) to Envarsus XR® (tacrolimus extended release) using an objective measure of cognition.
What is the current status of trial NCT03410654?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 28 participants. The study started on 2018-10-24. Estimated completion is 2024-07-01.
What interventions are being tested in trial NCT03410654?
The interventions under investigation include: Tacrolimus, Extended Release, (Envarsus Xr) (DRUG).
Who is sponsoring clinical trial NCT03410654?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03410654's enrollment target sits among peer trials
28 938th of 2000 higher than 1,038 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI